BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 17554481)

  • 1. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
    Zlatanović G; Jovanović S; Veselinović D; Zivković M
    Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
    Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
    Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
    Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab in refractory uveitis due to Behçet's disease.
    Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
    Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease.
    Capella MJ; Foster CS
    Ocul Immunol Inflamm; 2012 Jun; 20(3):198-202. PubMed ID: 22486265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab for sight-threatening uveitis in Behçet's disease.
    Mushtaq B; Saeed T; Situnayake RD; Murray PI
    Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
    Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
    Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF-alpha therapy for sight threatening uveitis.
    Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
    Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
    Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
    Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
    [No Abstract]   [Full Text] [Related]  

  • 19. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H; Okada AA; Watanabe T; Taki W
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
    Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
    Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.